Exemestane in early breast cancer: a review

by Michael Untch, Christian Jackisch
Published 2008-12-01

Statistical modelling of HER2-positivity in breast cancer: Final analyses from two large, multicentre, non-interventional studies in Germany

by Josef Rüschoff, Annette Lebeau, Peter Sinn, Hans-Ulrich Schildhaus, Thomas Decker, Johannes Ammann, Claudia Künzel, Winfried Koch, Michael Untch
Published 2020-02-01

Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC

by Sibylle Loibl, Carsten Denkert, Andreas Schneeweiss, Jens-Uwe Blohmer, Dirk-Michael Zahm, Marion van Mackelenbergh, Jörg Thomalla, Jens Huober, Christian Schem, Anja Mueller, Elmar Stickeler, Katharina Biehl, Michael Untch, Karsten Weber
Published 2020-07-01

Clinical Relevance of Collagen Protein Degradation Markers C3M and C4M in the Serum of Breast Cancer Patients Treated with Neoadjuvant Therapy in the GeparQuinto Trial

by Malgorzata Banys-Paluchowski, Sibylle Loibl, Isabell Witzel, Christoph Mundhenke, Bianca Lederer, Christine Solbach, Thomas Karn, Frederik Marmé, Valentina Nekljudova, Christian Schem, Elmar Stickeler, Nicholas Willumsen, Morten A. Karsdal, Michael Untch, Volkmar Müller
Published 2019-08-01

Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial

by Ines Stevic, Volkmar Müller, Karsten Weber, Peter A. Fasching, Thomas Karn, Frederic Marmé, Christian Schem, Elmar Stickeler, Carsten Denkert, Marion van Mackelenbergh, Christoph Salat, Andreas Schneeweiss, Klaus Pantel, Sibylle Loibl, Michael Untch, Heidi Schwarzenbach
Published 2018-10-01

Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto...

by Yasmin Issa-Nummer, Silvia Darb-Esfahani, Sibylle Loibl, Georg Kunz, Valentina Nekljudova, Iris Schrader, Bruno Valentin Sinn, Hans-Ullrich Ulmer, Ralf Kronenwett, Marianne Just, Thorsten Kühn, Kurt Diebold, Michael Untch, Frank Holms, Jens-Uwe Blohmer, Jörg-Olaf Habeck, Manfred Dietel, Friedrich Overkamp, Petra Krabisch, Gunter von Minckwitz, Carsten Denkert
Published 2013-01-01

Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto

by Elena Laakmann, Isabell Witzel, Peter A. Fasching, Mahdi Rezai, Christian Schem, Christine Solbach, Hans Tesch, Peter Klare, Andreas Schneeweiss, Christoph Salat, Dirk-Michael Zahm, Jens-Uwe Blohmer, Barbara Ingold-Heppner, Jens Huober, Claus Hanusch, Christian Jackisch, Mattea Reinisch, Michael Untch, Gunter von Minckwitz, Valentina Nekljudova, Volkmar Müller, Sibylle Loibl
Published 2019-05-01

Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy

by Serena Di Cosimo, Valentina Appierto, Sara Pizzamiglio, Marco Silvestri, José Baselga, Martine Piccart, Jens Huober, Miguel Izquierdo, Lorena de la Pena, Florentine S. Hilbers, Evandro de Azambuja, Michael Untch, Lajos Pusztai, Kathleen Pritchard, Paolo Nuciforo, Anne Vincent-Salomon, Fraser Symmans, Giovanni Apolone, Filippo G. de Braud, Marilena V. Iorio, Paolo Verderio, Maria Grazia Daidone
Published 2020-02-01

Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany

by Hanna Huebner, Christian M. Kurbacher, Geoffrey Kuesters, Andreas D. Hartkopf, Michael P. Lux, Jens Huober, Bernhard Volz, Florin-Andrei Taran, Friedrich Overkamp, Hans Tesch, Lothar Häberle, Diana Lüftner, Markus Wallwiener, Volkmar Müller, Matthias W. Beckmann, Erik Belleville, Matthias Ruebner, Michael Untch, Peter A. Fasching, Wolfgang Janni, Tanja N. Fehm, Hans-Christian Kolberg, Diethelm Wallwiener, Sara Y. Brucker, Andreas Schneeweiss, Johannes Ettl
Published 2020-11-01

Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuz...

by Laura L. Michel, Andreas D. Hartkopf, Peter A. Fasching, Hans-Christian Kolberg, Peyman Hadji, Hans Tesch, Lothar Häberle, Johannes Ettl, Diana Lüftner, Markus Wallwiener, Volkmar Müller, Matthias W. Beckmann, Erik Belleville, Bernhard Volz, Hanna Huebner, Pauline Wimberger, Carsten Hielscher, Christoph Mundhenke, Christian Kurbacher, Rachel Wuerstlein, Michael Untch, Friedrich Overkamp, Jens Huober, Wolfgang Janni, Florin-Andrei Taran, Michael P. Lux, Diethelm Wallwiener, Sara Y. Brucker, Andreas Schneeweiss, Tanja N. Fehm
Published 2020-10-01

Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry

by Michael P. Lux, Naiba Nabieva, Andreas D. Hartkopf, Jens Huober, Bernhard Volz, Florin-Andrei Taran, Friedrich Overkamp, Hans-Christian Kolberg, Peyman Hadji, Hans Tesch, Lothar Häberle, Johannes Ettl, Diana Lüftner, Markus Wallwiener, Volkmar Müller, Matthias W. Beckmann, Erik Belleville, Pauline Wimberger, Carsten Hielscher, Matthias Geberth, Wolfgang Abenhardt, Christian Kurbacher, Rachel Wuerstlein, Christoph Thomssen, Michael Untch, Peter A. Fasching, Wolfgang Janni, Tanja N. Fehm, Diethelm Wallwiener, Andreas Schneeweiss, Sara Y. Brucker
Published 2018-12-01

Corrigendum to “Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, H...

by Andreas Schneeweiss, Johannes Ettl, Diana Lüftner, Matthias W. Beckmann, Erik Belleville, Peter A. Fasching, Tanja N. Fehm, Matthias Geberth, Lothar Häberle, Peyman Hadji, Andreas D. Hartkopf, Carsten Hielscher, Jens Huober, Eugen Ruckhäberle, Wolfgang Janni, Hans Christian Kolberg, Christian M. Kurbacher, Evelyn Klein, Michael P. Lux, Volkmar Müller, Naiba Nabieva, Friedrich Overkamp, Hans Tesch, Elena Laakmann, Florin-Andrei Taran, Julia Seitz, Christoph Thomssen, Michael Untch, Pauline Wimberger, Rachel Wuerstlein, Bernhard Volz, Diethelm Wallwiener, Markus Wallwiener, Sara Y. Brucker
Published 2021-02-01

Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative bre...

by Andreas Schneeweiss, Johannes Ettl, Diana Lüftner, Matthias W. Beckmann, Erik Belleville, Peter A. Fasching, Tanja N. Fehm, Matthias Geberth, Lothar Häberle, Peyman Hadji, Andreas D. Hartkopf, Carsten Hielscher, Jens Huober, Eugen Ruckhäberle, Wolfgang Janni, Hans Christian Kolberg, Christian M. Kurbacher, Evelyn Klein, Michael P. Lux, Volkmar Müller, Naiba Nabieva, Friedrich Overkamp, Hans Tesch, Elena Laakmann, Florin-Andrei Taran, Julia Seitz, Christoph Thomssen, Michael Untch, Pauline Wimberger, Rachel Wuerstlein, Bernhard Volz, Diethelm Wallwiener, Markus Wallwiener, Sara Y. Brucker
Published 2020-12-01